Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis

Osteoarthritis is one of the world's leading causes of disability. Roughly 4.3% of adults have painful knee osteoarthritis, with knee pain on most days1; the prevalence of disease is much higher than this among older persons. The main nonsurgical treatments include nonsteroidal antiinflammatory drugs (NSAIDs) — which can be dangerous for older persons who are most often affected by this disease — and exercise, to which adherence is often poor. Acetaminophen has only modest efficacy and, as a consequence, has been removed from some treatment guidelines. New treatments are desperately needed.2-4 In this issue of the Journal, Bliddal et al.5 . . .